 Edward Hoffenberg
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 27 | 2023 | 264 | 4.010 |
Why?
| | Crohn Disease | 11 | 2019 | 196 | 2.180 |
Why?
| | Inflammatory Bowel Diseases | 10 | 2022 | 287 | 2.020 |
Why?
| | Colitis, Ulcerative | 6 | 2019 | 105 | 1.620 |
Why?
| | Transglutaminases | 18 | 2022 | 142 | 1.540 |
Why?
| | Autoantibodies | 17 | 2022 | 1354 | 1.420 |
Why?
| | Marijuana Use | 2 | 2018 | 167 | 0.940 |
Why?
| | Medical Marijuana | 3 | 2019 | 97 | 0.760 |
Why?
| | Cannabinol | 1 | 2019 | 2 | 0.660 |
Why?
| | Anti-Inflammatory Agents | 4 | 2017 | 451 | 0.650 |
Why?
| | Dronabinol | 1 | 2019 | 118 | 0.590 |
Why?
| | Arterio-Arterial Fistula | 1 | 2016 | 4 | 0.530 |
Why?
| | Hematemesis | 1 | 2016 | 3 | 0.530 |
Why?
| | Aneurysm, Infected | 1 | 2016 | 4 | 0.530 |
Why?
| | Esophageal Fistula | 1 | 2016 | 17 | 0.520 |
Why?
| | Mass Screening | 5 | 2011 | 1011 | 0.520 |
Why?
| | Intestinal Polyps | 2 | 2013 | 15 | 0.500 |
Why?
| | Aortic Coarctation | 1 | 2016 | 69 | 0.490 |
Why?
| | Marijuana Smoking | 1 | 2018 | 224 | 0.480 |
Why?
| | Aortic Diseases | 1 | 2016 | 109 | 0.470 |
Why?
| | Health Services Misuse | 1 | 2014 | 36 | 0.470 |
Why?
| | Adolescent | 29 | 2019 | 17826 | 0.450 |
Why?
| | Antibodies, Monoclonal | 4 | 2014 | 1270 | 0.450 |
Why?
| | Motivation | 1 | 2018 | 495 | 0.450 |
Why?
| | Intestinal Mucosa | 4 | 2015 | 530 | 0.450 |
Why?
| | Capsule Endoscopy | 2 | 2013 | 17 | 0.440 |
Why?
| | Gastrointestinal Agents | 3 | 2017 | 60 | 0.440 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 648 | 0.430 |
Why?
| | Sertoli Cell Tumor | 1 | 2013 | 2 | 0.430 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2013 | 8 | 0.430 |
Why?
| | Child | 37 | 2023 | 18362 | 0.430 |
Why?
| | Intussusception | 1 | 2013 | 27 | 0.430 |
Why?
| | Cerebral Palsy | 1 | 2013 | 80 | 0.390 |
Why?
| | Humans | 69 | 2023 | 114925 | 0.390 |
Why?
| | Heart Transplantation | 1 | 2017 | 667 | 0.380 |
Why?
| | Jejunum | 1 | 2011 | 24 | 0.370 |
Why?
| | Short Bowel Syndrome | 2 | 2011 | 20 | 0.370 |
Why?
| | Gliadin | 2 | 2007 | 12 | 0.370 |
Why?
| | Gastrointestinal Tract | 1 | 2013 | 169 | 0.360 |
Why?
| | Intestine, Small | 6 | 2013 | 122 | 0.350 |
Why?
| | Child, Preschool | 23 | 2018 | 9083 | 0.350 |
Why?
| | Diabetes Mellitus, Type 1 | 7 | 2017 | 3248 | 0.350 |
Why?
| | Pyloric Stenosis | 1 | 2010 | 3 | 0.350 |
Why?
| | Autoimmunity | 4 | 2011 | 818 | 0.350 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2009 | 102 | 0.350 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 87 | 0.350 |
Why?
| | Immunoglobulin A | 7 | 2022 | 171 | 0.340 |
Why?
| | Jejunal Diseases | 1 | 2009 | 7 | 0.340 |
Why?
| | Ibuprofen | 1 | 2010 | 74 | 0.330 |
Why?
| | Male | 37 | 2019 | 55655 | 0.320 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1182 | 0.310 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 372 | 0.310 |
Why?
| | Infliximab | 4 | 2017 | 94 | 0.300 |
Why?
| | Delivery of Health Care | 1 | 2014 | 834 | 0.290 |
Why?
| | Incidence | 5 | 2018 | 2316 | 0.290 |
Why?
| | Wheat Hypersensitivity | 1 | 2007 | 4 | 0.280 |
Why?
| | Quality Improvement | 1 | 2014 | 954 | 0.280 |
Why?
| | Colorado | 7 | 2018 | 4089 | 0.280 |
Why?
| | Female | 35 | 2019 | 59571 | 0.270 |
Why?
| | Nutritional Support | 1 | 2006 | 27 | 0.270 |
Why?
| | Gastroenterology | 3 | 2023 | 159 | 0.270 |
Why?
| | Enterocytes | 3 | 2003 | 14 | 0.250 |
Why?
| | Infusions, Parenteral | 1 | 2005 | 36 | 0.250 |
Why?
| | HLA-DQ Antigens | 3 | 2017 | 176 | 0.240 |
Why?
| | HLA-DR Antigens | 3 | 2017 | 220 | 0.230 |
Why?
| | Glutens | 5 | 2005 | 56 | 0.230 |
Why?
| | Antibodies, Fungal | 2 | 2005 | 9 | 0.230 |
Why?
| | Case-Control Studies | 6 | 2019 | 3008 | 0.230 |
Why?
| | Emergency Service, Hospital | 1 | 2014 | 1813 | 0.220 |
Why?
| | Diet, Gluten-Free | 2 | 2016 | 30 | 0.220 |
Why?
| | Pregnancy Outcome | 1 | 2006 | 337 | 0.220 |
Why?
| | Infant | 19 | 2018 | 7936 | 0.220 |
Why?
| | Time Factors | 7 | 2017 | 6125 | 0.220 |
Why?
| | Citrulline | 1 | 2003 | 39 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2017 | 2102 | 0.210 |
Why?
| | Antioxidants | 2 | 1997 | 530 | 0.210 |
Why?
| | Colonic Polyps | 2 | 2004 | 68 | 0.200 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2542 | 0.200 |
Why?
| | Child Development | 1 | 2006 | 387 | 0.200 |
Why?
| | Home Care Services | 1 | 2005 | 222 | 0.200 |
Why?
| | Sensitivity and Specificity | 5 | 2009 | 1700 | 0.190 |
Why?
| | Pregnancy Complications | 1 | 2006 | 430 | 0.190 |
Why?
| | Patient Satisfaction | 1 | 2005 | 583 | 0.180 |
Why?
| | Infant, Newborn | 10 | 2011 | 5035 | 0.180 |
Why?
| | Avena | 1 | 2000 | 4 | 0.180 |
Why?
| | Safety | 2 | 2017 | 297 | 0.170 |
Why?
| | Saccharomyces cerevisiae | 2 | 2005 | 477 | 0.170 |
Why?
| | Abdominal Pain | 2 | 1999 | 136 | 0.170 |
Why?
| | Predictive Value of Tests | 4 | 2007 | 1801 | 0.170 |
Why?
| | Administration, Oral | 2 | 2019 | 731 | 0.170 |
Why?
| | Autoimmune Diseases | 3 | 2017 | 392 | 0.170 |
Why?
| | Follow-Up Studies | 5 | 2017 | 4427 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 1134 | 0.160 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 1999 | 33 | 0.160 |
Why?
| | Cannabinoids | 2 | 2017 | 115 | 0.160 |
Why?
| | Government Regulation | 1 | 2019 | 46 | 0.160 |
Why?
| | Aminoglycosides | 1 | 2018 | 13 | 0.160 |
Why?
| | Diarrhea | 2 | 2018 | 173 | 0.160 |
Why?
| | Young Adult | 4 | 2019 | 10476 | 0.150 |
Why?
| | Risk Factors | 8 | 2017 | 8637 | 0.150 |
Why?
| | Radioimmunoassay | 3 | 2005 | 164 | 0.150 |
Why?
| | Clostridium Infections | 1 | 2018 | 56 | 0.150 |
Why?
| | Urine | 1 | 2017 | 55 | 0.150 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 4634 | 0.140 |
Why?
| | Biopsy, Needle | 2 | 2011 | 183 | 0.140 |
Why?
| | Feces | 3 | 2018 | 374 | 0.140 |
Why?
| | Retrospective Studies | 8 | 2023 | 12543 | 0.140 |
Why?
| | Endocannabinoids | 1 | 2017 | 37 | 0.140 |
Why?
| | Legislation, Drug | 1 | 2017 | 78 | 0.130 |
Why?
| | Numismatics | 1 | 2015 | 1 | 0.130 |
Why?
| | Failure to Thrive | 1 | 1996 | 32 | 0.130 |
Why?
| | Plasma | 1 | 2017 | 210 | 0.130 |
Why?
| | Duodenum | 4 | 2022 | 62 | 0.130 |
Why?
| | Case Management | 1 | 1996 | 62 | 0.130 |
Why?
| | Quality Assurance, Health Care | 1 | 2018 | 313 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 4406 | 0.130 |
Why?
| | Rotavirus Infections | 3 | 2006 | 50 | 0.130 |
Why?
| | Serologic Tests | 3 | 2007 | 49 | 0.130 |
Why?
| | Alagille Syndrome | 1 | 1995 | 35 | 0.120 |
Why?
| | Quality of Health Care | 2 | 2018 | 573 | 0.120 |
Why?
| | Biological Products | 1 | 2018 | 169 | 0.120 |
Why?
| | Colonoscopy | 1 | 2017 | 205 | 0.120 |
Why?
| | Critical Pathways | 1 | 1996 | 74 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 1 | 2017 | 413 | 0.120 |
Why?
| | Prospective Studies | 5 | 2019 | 6218 | 0.120 |
Why?
| | Pneumococcal Infections | 1 | 2016 | 91 | 0.120 |
Why?
| | Ileal Diseases | 1 | 2014 | 9 | 0.120 |
Why?
| | Prevalence | 3 | 2013 | 2251 | 0.120 |
Why?
| | Telemedicine | 1 | 2023 | 665 | 0.120 |
Why?
| | After-Hours Care | 1 | 2014 | 16 | 0.120 |
Why?
| | Streptococcus pneumoniae | 1 | 2016 | 134 | 0.120 |
Why?
| | Foreign Bodies | 1 | 2015 | 99 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2009 | 797 | 0.120 |
Why?
| | Colitis | 1 | 2017 | 226 | 0.120 |
Why?
| | Self Report | 1 | 2018 | 696 | 0.120 |
Why?
| | Gastrointestinal Diseases | 1 | 1996 | 183 | 0.120 |
Why?
| | Esophagus | 1 | 2015 | 226 | 0.110 |
Why?
| | Age Factors | 3 | 2013 | 2891 | 0.110 |
Why?
| | Reactive Oxygen Species | 1 | 1996 | 536 | 0.110 |
Why?
| | Biopsy | 3 | 2007 | 1045 | 0.110 |
Why?
| | Rotavirus | 4 | 2006 | 22 | 0.110 |
Why?
| | Laparoscopy | 1 | 1997 | 389 | 0.110 |
Why?
| | Treatment Outcome | 5 | 2018 | 9105 | 0.110 |
Why?
| | Rectal Fistula | 1 | 2013 | 21 | 0.110 |
Why?
| | Sertoli Cells | 1 | 2013 | 21 | 0.110 |
Why?
| | Health Plan Implementation | 1 | 2014 | 132 | 0.110 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 718 | 0.100 |
Why?
| | Stomach | 1 | 2013 | 101 | 0.100 |
Why?
| | Pigmentation | 1 | 2013 | 55 | 0.100 |
Why?
| | Colon | 2 | 2013 | 233 | 0.100 |
Why?
| | Cholestasis | 1 | 1995 | 224 | 0.100 |
Why?
| | Receptors, Virus | 1 | 2011 | 75 | 0.100 |
Why?
| | Cystic Fibrosis | 2 | 2015 | 956 | 0.100 |
Why?
| | Microvilli | 2 | 2001 | 70 | 0.100 |
Why?
| | Age of Onset | 1 | 2013 | 448 | 0.090 |
Why?
| | Quality of Life | 2 | 2019 | 2359 | 0.090 |
Why?
| | Risk Assessment | 2 | 2011 | 2975 | 0.090 |
Why?
| | Health Care Costs | 1 | 2014 | 380 | 0.090 |
Why?
| | Plant Proteins | 1 | 2011 | 81 | 0.090 |
Why?
| | Age Distribution | 1 | 2011 | 340 | 0.090 |
Why?
| | Sex Distribution | 1 | 2011 | 336 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2011 | 295 | 0.090 |
Why?
| | Hospitals, Pediatric | 1 | 2013 | 479 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2000 | 387 | 0.080 |
Why?
| | Reference Values | 1 | 2011 | 741 | 0.080 |
Why?
| | Diagnosis, Differential | 2 | 2007 | 1355 | 0.080 |
Why?
| | Cytomegalovirus Infections | 2 | 2001 | 183 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 1477 | 0.080 |
Why?
| | Practice Guidelines as Topic | 3 | 2023 | 1400 | 0.080 |
Why?
| | Prednisolone | 1 | 2009 | 77 | 0.080 |
Why?
| | Family | 1 | 2013 | 590 | 0.080 |
Why?
| | Antibodies, Viral | 3 | 2006 | 522 | 0.080 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1635 | 0.080 |
Why?
| | Antibodies | 1 | 2011 | 372 | 0.080 |
Why?
| | Gastrointestinal Microbiome | 1 | 2015 | 502 | 0.080 |
Why?
| | Adult | 7 | 2019 | 30604 | 0.080 |
Why?
| | Liver Transplantation | 1 | 1995 | 706 | 0.080 |
Why?
| | Prognosis | 3 | 2019 | 3344 | 0.080 |
Why?
| | Laboratories | 1 | 2009 | 95 | 0.080 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 546 | 0.070 |
Why?
| | Sex Factors | 1 | 2013 | 1721 | 0.070 |
Why?
| | Disease Progression | 1 | 2014 | 2392 | 0.070 |
Why?
| | Cafe-au-Lait Spots | 1 | 2007 | 3 | 0.070 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2009 | 204 | 0.070 |
Why?
| | Self-Help Groups | 1 | 2007 | 29 | 0.070 |
Why?
| | Cisapride | 1 | 2006 | 5 | 0.070 |
Why?
| | Apgar Score | 1 | 2006 | 16 | 0.070 |
Why?
| | Edible Grain | 1 | 2005 | 43 | 0.060 |
Why?
| | Infant, Low Birth Weight | 1 | 2006 | 125 | 0.060 |
Why?
| | Mycoses | 1 | 2005 | 66 | 0.060 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 104 | 0.060 |
Why?
| | Child Nutrition Disorders | 1 | 2004 | 16 | 0.060 |
Why?
| | Genetic Testing | 1 | 2007 | 379 | 0.060 |
Why?
| | Adenomatous Polyposis Coli | 2 | 2007 | 32 | 0.060 |
Why?
| | Growth | 1 | 2004 | 56 | 0.060 |
Why?
| | Cytoskeletal Proteins | 1 | 2004 | 145 | 0.060 |
Why?
| | Nutrition Assessment | 1 | 2004 | 75 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2007 | 668 | 0.050 |
Why?
| | Atrophy | 1 | 2003 | 151 | 0.050 |
Why?
| | Societies, Medical | 3 | 2018 | 677 | 0.050 |
Why?
| | Trans-Activators | 1 | 2004 | 368 | 0.050 |
Why?
| | Infant, Premature | 1 | 2006 | 478 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 1993 | 128 | 0.050 |
Why?
| | Patient Compliance | 1 | 2006 | 526 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 675 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2006 | 2382 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1856 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2000 | 133 | 0.040 |
Why?
| | Cohort Studies | 2 | 2003 | 4903 | 0.040 |
Why?
| | Food Hypersensitivity | 1 | 2004 | 254 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2007 | 1749 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2004 | 958 | 0.040 |
Why?
| | Genes, p53 | 1 | 1999 | 62 | 0.040 |
Why?
| | Genes, ras | 1 | 1999 | 91 | 0.040 |
Why?
| | Smoking | 1 | 2006 | 1391 | 0.040 |
Why?
| | Aneuploidy | 1 | 1999 | 85 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 581 | 0.040 |
Why?
| | Diet | 1 | 2005 | 1077 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 18 | 0.040 |
Why?
| | Biomarkers | 2 | 2009 | 3418 | 0.040 |
Why?
| | Limit of Detection | 1 | 2017 | 53 | 0.040 |
Why?
| | Anemia | 1 | 1999 | 144 | 0.040 |
Why?
| | Glutathione Peroxidase | 1 | 1997 | 41 | 0.040 |
Why?
| | Placebo Effect | 1 | 1997 | 51 | 0.040 |
Why?
| | North America | 1 | 2018 | 257 | 0.040 |
Why?
| | Receptors, Cannabinoid | 1 | 2017 | 13 | 0.040 |
Why?
| | Hospital Costs | 1 | 1997 | 103 | 0.030 |
Why?
| | Vitamin E | 1 | 1997 | 110 | 0.030 |
Why?
| | Body Mass Index | 1 | 2004 | 1961 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 1997 | 110 | 0.030 |
Why?
| | Homozygote | 2 | 2011 | 188 | 0.030 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 1996 | 24 | 0.030 |
Why?
| | GTP-Binding Proteins | 1 | 2017 | 139 | 0.030 |
Why?
| | Nursing Audit | 1 | 1996 | 6 | 0.030 |
Why?
| | Models, Nursing | 1 | 1996 | 26 | 0.030 |
Why?
| | Free Radical Scavengers | 1 | 1996 | 78 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 474 | 0.030 |
Why?
| | Free Radicals | 1 | 1996 | 99 | 0.030 |
Why?
| | Pediatric Nursing | 1 | 1996 | 39 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 1996 | 139 | 0.030 |
Why?
| | Glutathione | 1 | 1997 | 300 | 0.030 |
Why?
| | Disabled Persons | 1 | 1997 | 133 | 0.030 |
Why?
| | Phagocytes | 1 | 1996 | 90 | 0.030 |
Why?
| | Pregnancy | 2 | 2006 | 5525 | 0.030 |
Why?
| | Portoenterostomy, Hepatic | 1 | 1995 | 52 | 0.030 |
Why?
| | Rats | 1 | 2003 | 4963 | 0.030 |
Why?
| | Capsule Endoscopes | 1 | 2015 | 7 | 0.030 |
Why?
| | Radioligand Assay | 2 | 2009 | 43 | 0.030 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2015 | 29 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 563 | 0.030 |
Why?
| | Permeability | 1 | 2015 | 148 | 0.030 |
Why?
| | Nurse Practitioners | 1 | 1996 | 102 | 0.030 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2014 | 27 | 0.030 |
Why?
| | HLA Antigens | 2 | 2006 | 224 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 1754 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 177 | 0.030 |
Why?
| | Biliary Atresia | 1 | 1996 | 183 | 0.030 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 90 | 0.030 |
Why?
| | Gene Expression | 1 | 1999 | 1422 | 0.030 |
Why?
| | Animals | 4 | 2017 | 31837 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 1998 | 547 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 228 | 0.030 |
Why?
| | Survival Analysis | 1 | 1995 | 1220 | 0.030 |
Why?
| | Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2011 | 7 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 1775 | 0.020 |
Why?
| | Cricetulus | 1 | 2011 | 97 | 0.020 |
Why?
| | CHO Cells | 1 | 2011 | 138 | 0.020 |
Why?
| | Vacuoles | 2 | 2001 | 33 | 0.020 |
Why?
| | Cricetinae | 1 | 2011 | 254 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 737 | 0.020 |
Why?
| | Survival Rate | 1 | 1995 | 1644 | 0.020 |
Why?
| | Heterozygote | 1 | 2011 | 251 | 0.020 |
Why?
| | Morphogenesis | 1 | 2011 | 161 | 0.020 |
Why?
| | Transfection | 1 | 2011 | 870 | 0.020 |
Why?
| | Zebrafish Proteins | 1 | 2011 | 246 | 0.020 |
Why?
| | Thinness | 1 | 2009 | 87 | 0.020 |
Why?
| | Methyltransferases | 1 | 2009 | 61 | 0.020 |
Why?
| | Mutation | 1 | 1999 | 3353 | 0.020 |
Why?
| | Biomedical Research | 1 | 2014 | 585 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 172 | 0.020 |
Why?
| | Zebrafish | 1 | 2011 | 411 | 0.020 |
Why?
| | ROC Curve | 1 | 2009 | 448 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 799 | 0.020 |
Why?
| | Tuberculosis | 1 | 2009 | 241 | 0.020 |
Why?
| | Pediatrics | 1 | 2014 | 984 | 0.020 |
Why?
| | Inflammation | 1 | 2017 | 2485 | 0.020 |
Why?
| | Thyroglobulin | 1 | 2005 | 17 | 0.020 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 27 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2005 | 138 | 0.020 |
Why?
| | Genes, APC | 1 | 2004 | 13 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2005 | 176 | 0.020 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2004 | 18 | 0.020 |
Why?
| | Loss of Heterozygosity | 1 | 2004 | 41 | 0.020 |
Why?
| | Organ Specificity | 1 | 2005 | 270 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 1893 | 0.010 |
Why?
| | Phenotype | 1 | 2011 | 2817 | 0.010 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2004 | 97 | 0.010 |
Why?
| | Neutralization Tests | 2 | 1993 | 63 | 0.010 |
Why?
| | beta Catenin | 1 | 2004 | 220 | 0.010 |
Why?
| | Aging | 1 | 1992 | 1621 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 3549 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2004 | 449 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 791 | 0.010 |
Why?
| | United States | 1 | 2018 | 12209 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 2005 | 776 | 0.010 |
Why?
| | Immunity, Cellular | 2 | 1993 | 249 | 0.010 |
Why?
| | Research | 1 | 2004 | 395 | 0.010 |
Why?
| | Mice | 1 | 2017 | 14935 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2001 | 410 | 0.010 |
Why?
| | Family Relations | 1 | 1998 | 85 | 0.010 |
Why?
| | Autoradiography | 1 | 1996 | 70 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1996 | 34 | 0.010 |
Why?
| | Single-Blind Method | 1 | 1996 | 258 | 0.010 |
Why?
| | Middle Aged | 2 | 2007 | 26801 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1996 | 995 | 0.010 |
Why?
| | RNA, Viral | 1 | 1996 | 565 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 1992 | 18 | 0.010 |
Why?
| | Base Sequence | 1 | 1996 | 2118 | 0.010 |
Why?
| | Antibody Formation | 1 | 1993 | 267 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1996 | 2791 | 0.010 |
Why?
| | Fetal Blood | 1 | 1992 | 270 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 915 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1992 | 1045 | 0.000 |
Why?
| | Cell Line | 1 | 1993 | 2640 | 0.000 |
Why?
| | Aged | 1 | 1999 | 19120 | 0.000 |
Why?
|
|
Hoffenberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|